Figures Appear

PTO/SB/08A (10-01)
Approved for use through 10/31/2002.OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO				Complete if Known		
				Application Number	Net Yet Assigned 10/73454	
INFORMATION DISCLOSURE				Filing Date	Concurrently Herewith	
S	TATEMENT	BY A	APPLICANT	First Named Inventor	Nadji Sourena	
				Art Unit	N/A 16024	
	(use as many sheets as necessary)			Examiner Name	Not Yot Assigned COLEMA	
Sheet	1	of	1	Attorney Docket Number	01252/1200687-US1	

			U.S. PA	IENI DO	CUMENIS		
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Nar	ne of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		1.441.0 10	FOREIGN	PATENT I	DOCUMENTS		
Examiner	Cite No.1	Foreign Patent Docum	ment Pub	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant	
Initials*		Country Code ³ -Number ⁴ -Kind Co	ode ⁵ (if known) MA			Passages or Relevant	₽

LLC DATENT DOCUMENTS

¹Applicant's unique citation designation number (optional). ²See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³
Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
BC		J. Org. Chem, Eunice Chan, et al. "Total Synthesis of (8R)-3-(2-Deoxy-β-D-erythropentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d]1,3]diazepin-8-ol (Pentostatin), the Potent Inhibitor of Adenosine Deaminase ^{1a} ,47, 3457-3464, 1982.	
BC		J. Org. Chem, Thien Van Truong et al, "Chirospecific Synthesis of the Tetrahydroimidazodiazepinol Aglycon of Pentostatin and Its Analogues", 58, 6090-6096, 1993.	
BC		Submitted by Seiki Saito, et al., "Diethyl (2S,3R)-2-(N-tert-Butoxycarbonyl)Amino-3- Hydroxysuccinate", Vol. 73, 1995.	
BC		American Chemical Society, David C. Baker, "A Total Synthesis of Pentostatin," the Potent Inhibitor of Adenosine Deaminase", 0002-7863/79/1501-6127, 1979.	
BC		J. Heterocyclic Chem, D.C. Baker et al., "Studies Related to the Total Synthesis of Pentostatin. Approaches to the Synthesis of (8R)-3,6,7,8-Tetrahydroimidazo[4,5-d][diazepin-8-d and N-3 Alkyl Congeners (1a)", Vol 20, 629-634, 1983.	
BC		The Journal of Antibiotics, H.D. Hollis Showalter, et al., "Improved Production of Pentostatin and Identification of Fermentation Cometabolites", Vol. 45, No. 12, 1914-1918, 1982.	
B		Drugs of the Future, "Antihypertensive Calcium Channel Blocker, Vol. 15, No. 7, 1990.	$oxed{oxed}$
BC		J. Am Chem. Soc., Kazuhiro Haraguchi, et al. "Synthesis and Characterization of Oligodeoxynucleotides Containing Formamidopyrimidine Lesions and Nonhydrolyzable Analogues", 124, 3263-3269, 2002.	
BC		American Chemical Society, Brett C. Bookser, et al., "AMP Deaminase Inhibitors.2. Initial Discovery of a Non-Nucleotide Transition-State Inhibitor Series ¹ , Vol. 43, No. 8, 1495-1507, 2000.	
BC		J. Am. Chem. Soc., Mark D. Erion, et al., "Discovery of AMP Mimetics that Exhibit High Inhibitory Potency and Specificity for AMP Deaminase" 121, 308-319, 1999.	
BC		Nucleosides & Nucleotides, H. Jeanette Thomas, et al., "The Synthesis of Coformycin From 5-Amino-1-β-D-Ribofuranosylimidazole-4-Carboxamide", 5(4) 431-439, 1986.	
BC		Nucleosides & Nucleotides, Mikyung Hong, et al. "Irreversible, Tight-Binding Inhibition of Adenosine Deaminase By Coformycins: Inhibitor Structural Features That Contribute to the Mode of Enzyme Inhibition", 16(7-9), 1053-1057, 1997.	

(W:1012 Brenda Ca	oleman	Date Considered	72b. 19 2006

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant